Refractory and super-refractory status epilepticus - An update

Current Neurology and Neuroscience Reports

Volumn 14, Issue 6, 2014, Pages

  Hocker, Sara ^a   Tatum, William O ^b   LaRoche, Suzette ^c   Freeman, W David ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anesthesia; Critical care; EEG; Status epilepticus; Super refractory

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FOSPHENYTOIN SODIUM; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; KETAMINE; LORAZEPAM; METHYLPREDNISOLONE; MIDAZOLAM; PENTOBARBITAL; PHENOBARBITAL; PREDNISONE; PROPOFOL; PROTON PUMP INHIBITOR; RITUXIMAB; THIOPENTAL; VALPROIC ACID;

ANTIBODY DETECTION; ARTICLE; CONVULSION; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; EPILEPTIC STATE; FEVER; GAZE; HUMAN; NAUSEA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROPOFOL INFUSION SYNDROME; PROSPECTIVE STUDY; PROTEIN BINDING; REFRACTORY PERIOD; SOMNOLENCE; TRACHEOSTOMY; VENTILATOR ASSOCIATED PNEUMONIA; ADULT; ANIMAL; BRAIN; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; PATHOLOGY; STATUS EPILEPTICUS;

ADULT; ANIMALS; BRAIN; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; STATUS EPILEPTICUS;

EID: 84900553293     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0452-x     Document Type: Article

References (62)

1. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251-6.
2. Mayer SA, Classen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors and impact on outcome. Arch Neurol. 2002;59:205-10.
3. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534-9.
4. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698-702.
5. Shorvon SD, Trinka E. Proceedings of the 3rd London-Innsbruck colloquium on status epilepticus. Epilepsia. 2011;52 Suppl 8:1-85.
6. •• Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(10):2802-18. This article is an evidence-based review that screened review articles, book chapters, and 159 articles reporting therapy in RSE. The authors put forth an organized and thorough review of both pharmacological and nonpharmacological management options in RSE.
7. Wilder-Smith EP, Lim EC, Teoh HL, Sharma VK, Tan JJ, Chan BP, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap. 2005;34(7):417-20.
8. Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J Clin Neurophysiol. 1995;12(4):326-42.
9. Fujikawa DG. The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus. Brain Res. 1996;725:11-22.
10. 2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci. 1997;17:7532-40.
11. Mazarati AM, Wasterlain CG, Sankar R, Shin D. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res. 1998;801:251-3.
12. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814:179-85.
13. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl JMed. 1998;339:792-8.
14. Mazarati AM, Wasterlain CG. N-Methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;265:187-90.
15. A receptor membrane trafficking and synaptic localization. Pharmacol Ther. 2009;123:17-31.
16. Smith KR, Kittler JT. The cell biology of synaptic inhibition in health and disease. Curr Opin Neurobiol. 2010;20:550-6.
17. Naylor DE, Liu H, Niquet J, Wasterlain CG. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis. 2013;54:225-38.
18. Cock HR, Tong X, Hargreaves I, Heales SJR, Clark JP, Patsalos PN, et al. Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. Epilepsy Res. 2002;48:157-68.
19. Tan RY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: a systematic review. Epilepsy Res. 2010;91:111-22.
20. Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, et al. Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One. 2011;28:e18200.
21. David Y, Cacheaux LP, Ivens S, Lapilover E, Heinemann U, Kaufer D, et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis? J Neurosci. 2009;29:10588-99.
22. Friedman A, Dingledine R. Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia. 2011;52 Suppl 3:33-9.
23. Henshall DC. MicroRNAs in the pathophysiology and treatment of status epilepticus. Front Mol Neurosci. 2013;6:37.
24. Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631-7.
25. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591-600.
26. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54 Suppl 6:89-92.
27. Hocker S, Wijdicks EF, Rabinstein AA. Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurol Res. 2013;35(2):163-8.
28. Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates: ischemic cell change and its relation to ictal physiological events. Arch Neurol. 1973;28:10-7.
29. Meldrum B. Excitotoxicity and epileptic brain damage. Epilepsy Res. 1991;10:55-6.
30. Bleck TP. Electroencephalographic monitoring. In: Tobin MR, editor. Principles and practice of intensive care monitoring. New York: McGraw-Hill; 1998. p. 1035-46.
31. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70(1):72-7.
32. Wijdicks EF. The multifaceted care of status epilepticus. Epilepsia. 2013;54 Suppl 6:61-3.
33. Kowalski RG, Ziai WC, Rees RN, Werner Jr JK, Kim G, Goodwin H, et al. Third-line antiepileptic therapy and outcome in status epilepticus: the impact of vasopressor use and prolonged mechanical ventilation. Crit Care Med. 2012;40(9):2677-84.
34. Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL. Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia. 2009;50(6):1566-71.
35. Sutter R, Marsch S, Fuhr P, Kaplan PW, Rüegg S. Anesthetic drugs in status epilepticus: risk or rescue?: a 6-year cohort study. Neurology. 2014;82(8):656-64.
36. Kaplan PW. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: 'the cure may be worse than the disease'). Neurophysiol Clin. 2000;30:377-82.
37. Jordan KG, Hirsch LJ. In nonconvulsive status epilepticus (NCSE), treat to burst-suppression: pro and con. Epilepsia. 2006;47 Suppl 1:41-5.
38. Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, et al. High-dose midazolam infusion for refractory status epilepticus. Neurology. 2014;82(4):359-65.
39. Veldhoen ES, Hartman BJ, van Gestel JP. Monitoring biochemical parameters as an early sign of propofol infusion syndrome: false feeling of security. Pediatr Crit Care Med. 2009;10(2):e19-21.
40. Lowenstein D, Aminoff S, Smon R. Barbiturate anesthesia in status epilepticus: clinical experience of 14 patients. Neurology. 1988;38:395-400.
41. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117-22.
42. Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105(1-2):183-8.
43. •• Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498-503. Gaspard et al. reviewed the medical records and EEGs of 58 patients with 60 episodes of RSE treated with intravenously administered ketamine, and provide preliminary data on the safety and effective dose of ketamine in this setting.
44. Green SM, Cote CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med. 2009;54:181-90.
45. Thordstein M, Constantinescu R. Possibly lifesaving, noninvasive, EEG-guided neuromodulation in anesthesia-refractory partial status epilepticus. Epilepsy Behav. 2012;25(3):468-72.
46. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094-100. doi:10.1212/WNL.0b013e3182698cd8.
47. Liu A, Pang T, Herman S, Pascual-Leone A, Rotenberg A. Transcranial magnetic stimulation for refractory focal status epilepticus in the intensive care unit. Seizure. 2013;22(10):893-6.
48. Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82(8):665-70.
49. Moseley BD, Degiorgio CM. Refractory status epilepticus treated with trigeminal nerve stimulation. Epilepsy Res. 2014;108(3):600-3.
50. Shorvon S. Status epilepticus: its clinical features and treatment in children and adults. Cambridge: Cambridge University Press; 1994.
51. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344-9.
52. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43(2):146-53.
53. •• Kilbride RD, Reynolds AS, Szaflarski JP, Hirsch LJ. Clinical outcomes following prolonged refractory status epilepticus (PRSE). Neurocrit Care. 2013;18(3):374-85. Kilbide et al. reviewed 63 consecutive patients with prolonged (more than 1 week) RSE, finding that good outcome is not unusual in this population including some older patients, with a variety of diagnoses and despite months of coma. This study provides the best available outcome data in prolonged RSE.
54. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27-34.
55. Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66(11):1736-8.
56. Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol. 2009;66(12):1505-9.
57. Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsy Res. 2011;93(1):1-10.
58. Bausell R, Svoronos A, Lennihan L, Hirsch LJ. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology. 2011;77(15):1494-5.
59. Standley K, Abdulmassih R, Benbadis S. Good outcome is possible after months of refractory convulsive status epilepticus: lesson learned. Epilepsia. 2012;53(1):e17-20.
60. Jeon SB, Parikh G, Choi HA, Lee K, Lee JH, Schmidt JM, et al. Acute cerebral microbleeds in refractory status epilepticus. Epilepsia. 2013;54(5):e66-8.
61. Reddy K, Reife R, Cole AJ. SGE-102: a novel therapy for refractory status epilepticus. Epilepsia. 2013;54 Suppl 6:81-3.
62. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology. 2009;72:744-9.